Whalesbook
Toh Indegene ke latest results mein thoda confusion hai. Ek taraf company ne revenue mein record bana diya, jabki dusri taraf profit kaafi kam ho gaya. Investors ab soch rahe hain ki yeh margin pressure aur M&A costs aage jaakar growth ko kaise affect karenge.
Company ka revenue Q4 FY26 mein ₹1,003.4 crore tak pahunch gaya, jo pichhle saal se 32.8% zyada hai. Yeh pehli baar hai jab quarterly revenue ₹1,000 crore ke mark ko cross kiya hai. Dollar revenue bhi 25.6% badhkar $109.7 million ho gaya. Par yaar, iss top-line success ke peeche net profit mein 32.2% ki girawat aayi, jo ₹117.6 crore se ghata hokar ₹79.7 crore ho gaya. EBITDA toh 10.9% badhkar ₹163.6 crore hua, par margin 16.3% pe aa gaya, jo pehle 19.5% tha. Stock bhi thoda neeche 497.70 pe close hua, isse lagta hai investors profit ko zyada importance de rahe hain.
Ab baat karte hain margins ki. Indegene ka P/E ratio typically 27x se 31x rehta hai, jiska matlab hai investors achhi aur consistent profitability expect karte hain. Lekin yeh 16.3% ka EBITDA margin toh pichhle 4 saalon ke average 19%-20% se kaafi kam hai. CFO Suhas Prabhu ne bola ki yeh sab M&A ke one-time kharchon ki wajah se hua hai, jisme Q4 mein ₹20.3 crore ka loss bhi tha. Healthcare tech sector mein AI aur efficiency pe zor hai. Competitors jaise IQVIA Holdings ka P/E 24.8x hai. Indegene ka higher P/E unki growth aur profit expectation ko dikhata hai, jo latest results se thoda challenge ho sakta hai. Acquisitions jaise BioPharm aur WARN & Co. ne short-term mein margins pe pressure dala hai.
Yeh 32.2% net profit ki kami aur EBITDA margins ka 19.5% se 16.3% tak girna kaafi kuch bata raha hai. Company M&A costs ko blame kar rahi hai, par agar aise kharch aage bhi chalte rahe toh profitability pe asar padega. Indegene ka valuation P/E ratio peers se zyada hai, matlab unka valuation consistent profit growth pe depend karta hai. Par latest margin compression unki pricing power aur cost management pe sawaal utha raha hai. Analysts abhi bhi 'Buy' rating de rahe hain aur average target ₹568.57 hai, jo 15% se zyada upside dikhata hai. Lekin ek broker downgrade ne future risks bhi bata diye hain, agar margins jaldi recover nahi hue toh.
Analystlog kaafi positive hain, 'Buy' consensus aur ₹568.57 ka average target, kuch target toh ₹690 tak jaa rahe hain. Yeh Indegene ki long-term growth, especially client base aur GenAI initiatives pe bharosa dikhata hai. Management ne bola ki 53 clients ab $1 million annual revenue generate karte hain. Company FY27 mein momentum build karne ko lekar confident hai, jisme sales pipeline aur efficient revenue generation help karegi. Operational cash flow 47.3% badhkar ₹650.8 crore ho gaya hai, jo dividend dene ke liye kafi hai. Lekin investors ab FY27 forecasts pe nazar rakhenge ki company integration costs kaise manage karti hai aur consistent profitability kaise achieve karti hai.